Psyence Group Inc. (PSYGF)
USD 0.3
(0.0%)
USD 0.3
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -5.16 Million CAD | 15.21% |
| 2023 | -6.08 Million CAD | -32.53% |
| 2022 | -4.59 Million CAD | -4865.49% |
| 2021 | -92.51 Thousand CAD | -385.47% |
| 2020 | -19.05 Thousand CAD | 58.41% |
| 2019 | -45.82 Thousand CAD | -129.44% |
| 2018 | -19.97 Thousand CAD | 63.55% |
| 2017 | -54.79 Thousand CAD | -272.97% |
| 2016 | -14.69 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -5.25 Million CAD | 13.6% |
| 2024 Q4 | -1.72 Million CAD | -99.26% |
| 2024 Q3 | -864.53 Thousand CAD | -96.97% |
| 2024 Q2 | -438.91 Thousand CAD | 80.35% |
| 2024 Q1 | -2.23 Million CAD | 20.82% |
| 2023 Q3 | -1.1 Million CAD | -10.81% |
| 2023 Q4 | -2.82 Million CAD | -156.35% |
| 2023 Q1 | -1.17 Million CAD | -10.28% |
| 2023 FY | -6.08 Million CAD | -32.53% |
| 2023 Q2 | -993.11 Thousand CAD | 15.35% |
| 2022 FY | -4.59 Million CAD | -4865.49% |
| 2022 Q3 | -1.21 Million CAD | -8.66% |
| 2022 Q2 | -1.11 Million CAD | 6.53% |
| 2022 Q1 | -1.19 Million CAD | 42.55% |
| 2022 Q4 | -1.06 Million CAD | 12.45% |
| 2021 FY | -92.51 Thousand CAD | -385.47% |
| 2021 Q4 | -2.08 Million CAD | -2753.4% |
| 2021 Q2 | -7620.00 CAD | 86.3% |
| 2021 Q3 | -72.98 Thousand CAD | -857.74% |
| 2021 Q1 | -55.6 Thousand CAD | 0.0% |
| 2020 FY | -19.05 Thousand CAD | 58.41% |
| 2019 FY | -45.82 Thousand CAD | -129.44% |
| 2018 FY | -19.97 Thousand CAD | 63.55% |
| 2017 FY | -54.79 Thousand CAD | -272.97% |
| 2016 FY | -14.69 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | 100.063% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | 100.03% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | 100.074% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 87.008% |
| Novartis AG | 9.76 Billion USD | 100.053% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 100.0% |